The funding will be used to advance a study of Cognito’s flagship neuromodulation device. The latest funding round brings the company’s total raised to $93 million, according to a March 22 Cognito news release.
FoundersX Ventures led the financing round.
“This funding will accelerate development of Cognito’s home-based wearable device which has the potential to be a novel, safe, disease-modifying therapeutic approach to treat neurodegenerative diseases, starting with Alzheimer’s,” Cognito CEO Brent Vaughan said in the release.
